Literature DB >> 31567465

Evaluation of Traditional Chinese Medicine Herbs in Oncology Clinical Trials.

Jie Liu1,2, Jun J Mao2, Xin Shelley Wang3, Hongsheng Lin1.   

Abstract

Despite wide empirical use and demand for traditional Chinese medicine (TCM) herbs worldwide, high-quality clinical trials of TCM herbs in oncology are limited. We developed recommendations for rigorous clinical trials to evaluate their safety and efficacy for oncology patients. To accomplish this goal, the TCM & Cancer Research Committee of the Chinese Pharmaceutical Association convened a working group of oncologists, TCM experts, clinical researchers, biostatisticians, and industry/government representatives to develop principles and approaches for TCM cancer drug clinical trials. They identified 2 categories of herbal drugs based on therapeutic intent: survival improvement and symptom management. The working group also emphasized the need to adopt international standards when appropriate for TCM herbal drug approval and to develop methodology to standardize diagnostic criteria, treatment approaches, and outcome measures according to defining TCM characteristics. These recommendations aim to improve study design and methods to inform rigorous investigation of TCM herbs in patients with cancer.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31567465     DOI: 10.1097/PPO.0000000000000404

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  6 in total

1.  Alpinetin suppresses CYP3A4, 2C9, and 2E1 activity in vitro.

Authors:  Hongming Song; Chuankui Wei; Wu Yang; Zhaohe Niu; Mingkai Gong; Haiyan Hu; Haibo Wang
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

Review 2.  Research Status and Molecular Mechanism of the Traditional Chinese Medicine and Antitumor Therapy Combined Strategy Based on Tumor Microenvironment.

Authors:  Yang Zhang; Yanni Lou; Jingbin Wang; Cunguo Yu; Wenjuan Shen
Journal:  Front Immunol       Date:  2021-01-21       Impact factor: 7.561

Review 3.  Ferroptosis as a novel form of regulated cell death: Implications in the pathogenesis, oncometabolism and treatment of human cancer.

Authors:  Feifei Pu; Fengxia Chen; Zhicai Zhang; Deyao Shi; Binlong Zhong; Xiao Lv; Andrew Blake Tucker; Jiaming Fan; Alexander J Li; Kevin Qin; Daniel Hu; Connie Chen; Hao Wang; Fang He; Na Ni; Linjuan Huang; Qing Liu; William Wagstaff; Hue H Luu; Rex C Haydon; Le Shen; Tong-Chuan He; Jianxiang Liu; Zengwu Shao
Journal:  Genes Dis       Date:  2020-12-04

Review 4.  Antitumor effects of Chinese herbal medicine compounds and their nano-formulations on regulating the immune system microenvironment.

Authors:  Kexiang Sun; Linguangjin Wu; Shuyun Wang; Wanli Deng
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

5.  Symptom burden and willingness to participate: implications for herbal clinical trials in lung cancer.

Authors:  Jie Liu; Wei Hou; Mithat Gönen; Christina Seluzicki; Susan Qing Li; Jun J Mao
Journal:  Ann Palliat Med       Date:  2020-12-17

6.  Preliminary Efficacy and Safety of Reishi & Privet Formula on Quality of Life Among Non-Small Cell Lung Cancer Patients Undergoing Chemotherapy: A Randomized Placebo-Controlled Trial.

Authors:  Jie Liu; Jun J Mao; Susan Qing Li; Hongsheng Lin
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.